Nguyen H Tran, Mathias E Palmer, Angela Ulrich, Shaylene A McCue, Amit Mahipal, Wen Wee Ma, Hani M Babiker, Umair Majeed, Thorvardur R Halfdanarson, Robert R McWilliams, Zhaohui Jin, Ryan Carr, Lionel Aurelien Kankeu Fonkoua, Leslie Washburn, Caitlin Conboy, Rondell P Graham, Michael Torbenson, Patrick Starlinger, Krishan R Jethwa, Christopher Hallemeier, Alexander Revzin, Scott M Thompson, Ajit H Goenka, Sudhakar K Venkatesh, Mohamad B Sonbol, Mitesh J Borad, Tanios Bekaii-Saab, Gregory J Gores, Lewis R Roberts, Julie K Heimbach, Fang-Shu Ou
Futibatinib plus pembrolizumab demonstrated an acceptable safety profile but did not meet efficacy thresholds supporting further study in FGF19-expressing HCC. Effective post-immunotherapy treatment strategies remain an unmet need.
BACKGROUND: Optimal treatment following first-line immunotherapy for advanced hepatocellular carcinoma (HCC) remains uncertain. This study evaluated futibatinib, a pan-FGFR inhibitor, combined with pembrolizumab in previously treated patients with FGF19-expressing HCC.
METHODS: Eligible patients were ≥18 years old with advanced HCC, prior systemic therapy, Child-Pugh A-B7 liver function, ECOG 0-2, and FGF19 overexpression. Patients received futibatinib 20 mg orally daily plus pembrolizumab 200 mg intravenously every 3 weeks. The primary endpoint was progression-free survival at 6 months (PFS6). Secondary endpoints included overall survival (OS), objective response rate (ORR), quality of life, and safety.
RESULTS: Between August 2021 and March 2024, 14 patients enrolled and 13 were evaluable. Median age was 72 years (range, 60-87), 53.8% were male, 92.3% had Child-Pugh A liver function, and all had received prior immunotherapy. Median progression-free survival was 15 weeks (95% CI, 9.0-NE), with a PFS6 rate of 23.1% (95% CI, 8.6-62.3%). ORR was 0% (95% CI, 0-24.7%), while stable disease was observed in 53.9% of patients. Median OS was 55.7 weeks (95% CI, 47.3-NE). Grade ≥3 adverse events occurred in 69.2% of patients, and grade ≥4 adverse events in 15.4%. One grade 5 event (acute-on-chronic kidney injury) was deemed unrelated to treatment. Common adverse events included hyperphosphatemia, fatigue, diarrhea, elevated transaminases, dry eye, nail changes, rash, and oral mucositis.
CONCLUSIONS: Futibatinib plus pembrolizumab demonstrated an acceptable safety profile but did not meet efficacy thresholds supporting further study in FGF19-expressing HCC. Effective post-immunotherapy treatment strategies remain an unmet need.